Auris Health, Ethicon ’ s NeuWave ink robot-assisted bronchoscope ablation dev deal

Auris Health, previously known as Auris Surgical Robotics, said today it inked a cooperative development and commercialization deal with Johnson &Johnson (NYSE:JNJ) division Ethicon’s NeuWave Medical subsidiary looking to develop systems for the robotically-assisted bronchoscopic ablation of lung lesions. Through the agreement, both companies will help develop an integrated system for robotic control, navigation and application of bronchoscope-delivered microwave ablation. The bronchoscope in development will be equipped with a small camera and accessory channel to allow tools to enter the lungs through the mouth, Auris said. “For those treating people with suspicious nodules in the lung, the holy grail is to one day be able to detect and treat the disease in a single procedure. When this option becomes a reality, we may see many patients seek early screening and minimally invasive treatment,” Dr. Kazuhiro Yasufuku of the University of Toronto said in a prepared release. The development deal also covers tech optimization and procedure development, Redwood City, Calif.-based Auris said. “From the beginning, our vision has been to create a platform capable of enabling advanced diagnosis and therapy for a spectrum of disease, using the least-invasive approach. We are honored to have Ethicon as a partner. Through this collaboration, we believe we are taking a significant first step together toward making the goal of diagnosing and treating lung ca...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Endoscopic / Arthroscopic Respiratory Robotics aurishealth Ethicon johnsonandjohnson NeuWave Medical Inc. Source Type: news

Related Links:

AbstractAlectinib (Alecensa®) is a potent and highly selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor. Oral alectinib monotherapy is approved in the EU as first-line treatment for adults with advancedALK-positive non-small cell lung cancer (NSCLC) and for the treatment of adults with advancedALK-positive NSCLC previously treated with crizotinib. In the USA, alectinib is indicated for the treatment of adults withALK-positive metastatic NSCLC. The recommended dosage for alectinib in the EU and USA is 600  mg twice daily. Well-designed phase III studies in patients withALK-positive NSCLC showed th...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
CONCLUSIONS High expression of KRT17 is frequent in LAC tissues, which promotes tumor proliferation and invasion, and is correlated with a poor overall survival. Targeting KRT17 may be a novel direction for LAC drug development. PMID: 29991674 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
CONCLUSION: Together, these findings suggested that SIRT7 suppressed EMT in OSCC metastasis by promoting SMAD4 deacetylation. PMID: 30001742 [PubMed - in process]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: J Exp Clin Cancer Res Source Type: research
In conclusion, apatinib shows some efficacy in heavily treated NSCLC and generally tolerable toxicity in non-squamous NSCLC. More solid evidence will be accessible in near future.
Source: Saudi Journal of Biological Sciences - Category: Biology Source Type: research
ConclusionsA large proportion of the study patients started minocycline before grade 2 rash development and the severity of afatinib-related rash was lower than that previously reported. Oral TCs may be beneficial, especially if started early.
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
In conclusion, apatinib shows some efficacy in heavily treated NSCLC and generally tolerable toxicity in non-squamous NSCLC. More solid evidence will be accessible in near future.
Source: Saudi Journal of Biological Sciences - Category: Biology Source Type: research
AbstractOsimertinib (Tagrisso®) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating mutations over wild-type EGFR in patients with advanced non-small cell lung cancer (NSCLC), including the T790M mutation that often underlies acquired resistance to earlier generation EGFR TKIs. Relative to standard of care first-generation EGFR TKIs (erlotinib or gefitinib) as first-line treatment ofEGFR activating mutation-positive advanced NSCLC, osimertinib significantly prolongs median progression-free survival (PFS), with sep...
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
ConclusionsA large proportion of the study patients started minocycline before grade 2 rash development and the severity of afatinib-related rash was lower than that previously reported. Oral TCs may be beneficial, especially if started early.
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
Conclusions: Our study demonstrated the efficacy and safety of docetaxel plus ramucirumab with PEG-G-CSF in clinical practice. Primary prophylactic PEG-G-CSF could markedly reduce incidence of FN. Methods: We retrospectively reviewed medical records of pretreated NSCLC cases who had received docetaxel plus ramucirumab in our departments. PMID: 29963237 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Conclusions OMV produced non-negligible survival in patients and also showed stable long-term blood concentrations. The schedule of 20 –30 mg every other day without interruption gave good tolerability and clinical benefit.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Arthroscopy | Bronchoscopy | Cancer | Cancer & Oncology | Endoscopy | Lung Cancer | Medical Ethics | Oral Cancer | Respiratory Medicine